Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05895786 | A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] | PHASE3 | RECRUITING | 318 | — | — | May 20, 2023 | Jul 28, 2027 | Jun 1, 2026 | 146 | United States, Argentina +18 |
Total Improvement Score 0 to 100 with higher scores indicating a better outcome.
| Arm | Type | Description |
|---|---|---|
| PF-06823859 | EXPERIMENTAL | Participants will receive PF-06823859 via intravenous infusion every 4 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo via intravenous infusion every 4 weeks. |
| Name | Type | Description |
|---|---|---|
| PF-06823859 | DRUG | anti-interferon beta therapy |
| Placebo | DRUG | Placebo for PF-06823859 |
Inclusion Criteria: * Male or female adults (≥18 years old or minimum legal adult age as defined per local regulation, whichever is greater) * Active dermatomyositis (DM) or polymyositis (PM) with age of onset * 18 years old. * Must be receiving a stable dose of standard of care (SOC) background...